<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00820755</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62240-506</org_study_id>
    <nct_id>NCT00820755</nct_id>
  </id_info>
  <brief_title>Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <acronym>NEXT</acronym>
  <official_title>Open, Randomized, Multinational Phase IIIb Trial Evaluating the Activity and Safety of Cetuximab as 250 mg/m^2 Weekly and 500 mg/m^2 Every Two Weeks Maintenance Therapy After Platinum-based Chemotherapy in Combination With Cetuximab as First-line Treatment for Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      This open-label, randomized, multinational, non-comparative, phase IIIb trial with 2 parallel
      groups will screen about 1400 subjects with stage IIIB non-small cell lung cancer (NSCLC)
      with pleural effusion or stage IV NSCLC. It is expected that of approximately 1200 (85
      percent) subjects who will be included, about 1000 will be Caucasian; about 120 Asian, and
      the remainder (about 80) will be of other ethnic origin (that is neither Caucasian nor
      Asian). Approximately 480 (40 percent) subjects are expected to be free of progression at the
      end of combination treatment with cetuximab and platinum-based chemotherapy. These subjects
      will be eligible for randomization to intravenous cetuximab maintenance therapy with either
      500 milligram per square meter (mg/m^2) every 2 weeks or 250 mg/m^2 weekly (q1w); about 240
      subjects are expected per group.

      The trial will be performed in a community practice setting, with approximately 230 centers
      participating in the trial worldwide (planned countries are Argentina, Australia, Austria,
      Belgium, Brazil, Chile, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong,
      Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Russia,
      Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey, United
      Kingdom and Venezuela). With noncompetitive enrollment, approximately 4 to 8 subjects are
      expected to be enrolled at each center. Enrollment in the individual centers is generally
      limited to a maximum of 8 subjects. If any of these subjects does not receive trial treatment
      for any reason or discontinue all trial treatment at the first visit, additional subjects may
      be enrolled until 8 subjects were treated. The primary endpoint of the trial will be overall
      survival time from inclusion into the trial to death. Additional secondary efficacy endpoints
      will be time to treatment failure, tumor response, and disease control rate. Other endpoints
      will include safety and toxicity, compliance with maintenance therapy, subject satisfaction
      and translational research (TR) (for subjects with tumor samples available).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS) Time</measure>
    <time_frame>Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
    <description>The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With 1-year Overall Survival</measure>
    <time_frame>Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until one year after the last participant was included (March 2010)</time_frame>
    <description>The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)</measure>
    <time_frame>Time from randomization in cetuximab maintenance regimen to death or last day known to be alive, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)</time_frame>
    <description>The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Time from trial inclusion to treatment failure or last drug intake, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
    <description>Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)</measure>
    <time_frame>Time from randomization in cetuximab maintenance regimen to treatment failure or last drug intake, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)</time_frame>
    <description>Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase</measure>
    <time_frame>Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)</time_frame>
    <description>The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period</measure>
    <time_frame>Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
    <description>The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control in the Combination Therapy Phase</measure>
    <time_frame>Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)</time_frame>
    <description>The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control for the Whole Study Period</measure>
    <time_frame>Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
    <description>The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab 500 mg/m^2 every 2 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab 250 mg/m^2 weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab plus Platinum-based Doublet Chemotherapy</intervention_name>
    <description>Single first dose of cetuximab 400 mg/m^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram*hour/milliliter (mg*hr/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.</description>
    <arm_group_label>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab 500 mg/m^2</intervention_name>
    <description>Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Cetuximab 500 mg/m^2 every 2 weeks</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab 250 mg/m^2</intervention_name>
    <description>Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
    <arm_group_label>Cetuximab 250 mg/m^2 weekly</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has given written informed consent before any trial-related activities are
             carried out

          -  Male or female, greater than or equal to (&gt;=)18 years of age at the time of informed
             consent, inpatient or outpatient

          -  Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIB NSCLC with
             pleural effusion or stage IV

          -  Presence of at least 1 uni-dimensionally measurable index lesion, whereby index
             lesions must not lie in a previously irradiated area

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at
             inclusion in the trial

          -  White blood count&gt;= 3 * 10^9 per liter (/L) with neutrophils &gt;= 1.5 * 10^9 /L ,
             platelet count &gt;=100 * 10^9 /L , and hemoglobin &gt;= 5.6 millimole per liter (mmol/L) (9
             gram per deciliter [g/dL])

          -  Total bilirubin less than or equal to (=&lt;)1.5 * upper limit of normal (ULN) range

          -  Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) =&lt; 5 * ULN

          -  Glomerular filtration rate (GFR) &gt;=60 milliliter per minute (mL/min). The creatinine
             clearance (CrCl) estimated based on the Cockroft-Gault formula is used as a surrogate
             for the GFR

          -  Effective contraception that is, barrier method (condoms, diaphragm), oral, injectable
             or implant birth control, for both male and female subjects during the whole trial
             period and for at least 6 months after the end of trial treatment, if the risk of
             conception exists

          -  Recovered from relevant toxicities prior to inclusion in the trial

        Exclusion Criteria:

          -  Previous exposure to Epidermal Growth Factor Receptor (EGFR)-targeting therapy

          -  Previous chemotherapy for NSCLC; neo-adjuvant or adjuvant (radio-)chemotherapy is
             allowed if it was finished 6 months prior to start of trial treatment

          -  Major surgery within 30 days prior to inclusion in the trial

          -  Prior chest irradiation within 90 days prior to inclusion in the trial (palliative
             radiation of bone lesions is allowed)

          -  Participation in another clinical trial or treatment with any investigational agent(s)
             within 30 days prior to inclusion in the trial

          -  Concurrent chronic systemic immune therapy, chemotherapy for disease other than
             cancer, or hormone therapy for the treatment of cancer not indicated in the trial
             protocol

          -  Documented or symptomatic brain metastasis

          -  Pre-existing ascites Grade &gt;= 2 and/or pericardial effusion Grade &gt;= 2

          -  Superior vena cava syndrome contra-indicating hydration

          -  Previous malignancy in the last 5 years except basal cell carcinoma of the skin or
             pre-invasive carcinoma of the cervix

          -  Active infection (infection requiring intravenous antibiotics), including active
             tuberculosis, known and declared human immunodeficiency virus (HIV)

          -  Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled
             congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder despite
             treatment

          -  Known hypersensitivity reaction to any of the components of trial treatments

          -  Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria
             (NCI-CTC) Grade &gt;= 2 and/or ototoxicity Grade &gt;= 2, except if due to trauma or
             mechanical impairment due to tumor mass

          -  History of significant neurologic or psychiatric disorders including dementia,
             seizures, bipolar disorder

          -  Medical or psychological condition that would not permit the subject to complete the
             trial or sign informed consent

          -  Legal incapacity or limited legal capacity

          -  Known drug abuse

          -  Pregnancy (absence to be confirmed by serum beta-human chorionic gonadotropin
             [beta-HCG test]) or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Heeger, MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Contact</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2009</study_first_posted>
  <results_first_submitted>July 1, 2013</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2014</results_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First/last participants (informed consent): January 2009/17 March 2010. Clinical data cut-off: 17 December 2011</recruitment_details>
      <pre_assignment_details>Enrolled: 673 screened for eligibility; 90 excluded (mainly non-fulfillment of inclusion or exclusion criteria). 583 participants started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</title>
          <description>Combination Phase: Single first dose of cetuximab 400 milligram per square meter (mg/m^2) infusion administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min weekly (q1w) with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy infusion intravenously as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 mg*hour/milliliter (mg*h/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*h/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
          <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
        </group>
        <group group_id="P3">
          <title>Cetuximab 250 mg/m^2 Weekly</title>
          <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Combination Therapy Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="583"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313">2 of 313 participants excluded from maintenance phase analysis (reason: not eligible)</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sympt. deterioration w/o PD by imaging</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Maintenance Therapy Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Investigational study phase ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</title>
          <description>Combination Phase: Single first dose of cetuximab 400 milligram per square meter (mg/m^2) infusion administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min weekly (q1w) with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy infusion intravenously as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 mg*hour/milliliter (mg*h/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*h/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="9.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS) Time</title>
        <description>The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.</description>
        <time_frame>Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
        <population>Intention-to-treat (ITT) maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on computer tomography [CT] or magnetic resonance imaging [MRI] scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Time</title>
          <description>The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.</description>
          <population>Intention-to-treat (ITT) maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on computer tomography [CT] or magnetic resonance imaging [MRI] scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="13.6" upper_limit="18.2"/>
                    <measurement group_id="O2" value="15.5" lower_limit="13.2" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)</title>
        <description>The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.</description>
        <time_frame>Time from randomization in cetuximab maintenance regimen to death or last day known to be alive, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)</time_frame>
        <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Time (From Randomization to Cetuximab Maintenance Regimen Until Death)</title>
          <description>The OS time is defined as the time from randomization in cetuximab maintenance regimen to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier.</description>
          <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="10.1" upper_limit="14.8"/>
                    <measurement group_id="O2" value="12.6" lower_limit="9.3" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory analysis to test the null hypothesis of no difference between maintenance therapy regimen. Model is adjusted by histology (interactive voice response system [IVRS]) and tumor response status at the end of combination therapy (‘complete response [CR] or partial response [PR]’ versus ‘other’).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1265</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.959</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.736</ci_lower_limit>
            <ci_upper_limit>1.250</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.</description>
        <time_frame>Time from trial inclusion to treatment failure or last drug intake, reported between day of first participant included, that is, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
        <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to treatment failure is defined as the time from trial inclusion to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of inclusion (Day 1) if they received no study drug.</description>
          <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="6.6" lower_limit="6.1" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)</title>
        <description>Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.</description>
        <time_frame>Time from randomization in cetuximab maintenance regimen to treatment failure or last drug intake, reported between day of first participant randomized, that is, May 2009 until cut-off date (17 Dec 2011)</time_frame>
        <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (From Randomization to Cetuximab Maintenance Regimen Until Death)</title>
          <description>Time from randomization in cetuximab maintenance regimen to date of either first occurrence of progression, discontinuation of treatment due to progression or adverse event, withdrawal of consent or lost to follow up, start of further anticancer therapy, or death, whichever is earlier. Participants without events are censored either at the time of their last drug intake, or on the day of randomization (Day 1 of maintenance therapy) if they received no study drug.</description>
          <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.1" upper_limit="2.8"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.6" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory analysis to test the null hypothesis of no difference between maintenance therapy regimen. Model is adjusted by histology (IVRS) and tumor response status at the end of combination therapy (‘CR or PR’ versus ‘other’).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0622</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.774</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.613</ci_lower_limit>
            <ci_upper_limit>0.976</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase</title>
        <description>The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)</time_frame>
        <population>ITT analysis set included all participants enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</title>
            <description>Combination Phase: Single first dose of cetuximab 400 milligram per square meter (mg/m^2) infusion administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min weekly (q1w) with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy infusion intravenously as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 mg*hour/milliliter (mg*h/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*h/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Best Unconfirmed Tumor Response in the Combination Therapy Phase</title>
          <description>The response rate is defined as the percentage of participants having achieved complete response (CR) or partial response (PR) as the unconfirmed best overall response (BOR) according to centrally reviewed investigator assessments based on an independent review charter (IRC). As per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <population>ITT analysis set included all participants enrolled in this study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" lower_limit="32.3" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period</title>
        <description>The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
        <time_frame>Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
        <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant With Best Unconfirmed Tumor Response for the Whole Study Period</title>
          <description>The response rate is defined as the percentage of participants having achieved CR and PR as the BOR according to IRC assessment in combination therapy phase and radiological assessments (based on response evaluation criteria in solid tumors [RECIST] Version 1.0) in the maintenance therapy phase. As per RECIST v1.0 for target lesions and assessed by MRI: CR = Disappearance of all target lesions; PR = at least 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR</description>
          <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8" lower_limit="46.6" upper_limit="62.7"/>
                    <measurement group_id="O2" value="57.8" lower_limit="49.6" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Control in the Combination Therapy Phase</title>
        <description>The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.</description>
        <time_frame>Evaluations were performed every 2 cycles during combination therapy period until progression and at the end of combination therapy period, reported between day of first participant included, that is, Jan 2009, until cut-off date, (17 Dec 2011)</time_frame>
        <population>ITT analysis set included all participants enrolled in this study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</title>
            <description>Combination Phase: Single first dose of cetuximab 400 milligram per square meter (mg/m^2) infusion administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min weekly (q1w) with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy infusion intravenously as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 mg*hour/milliliter (mg*h/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*h/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Control in the Combination Therapy Phase</title>
          <description>The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed BOR according to IRC assessment.</description>
          <population>ITT analysis set included all participants enrolled in this study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" lower_limit="61.7" upper_limit="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Control for the Whole Study Period</title>
        <description>The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.</description>
        <time_frame>Evaluations were performed every 2 cycles during combination therapy and 6-weekly during maintenance therapy period until progression and at end of both periods, reported between day of first participant included, Jan 2009 until cut-off date (17 Dec 2011)</time_frame>
        <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Control for the Whole Study Period</title>
          <description>The disease control rate is defined as the percentage of participants having achieved complete response or partial response or stable disease as the unconfirmed best overall response according to IRC assessment in combination therapy phase and radiological assessments (based on RECIST Version 1.0 criteria) in the maintenance therapy phase.</description>
          <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="95.5" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.4" lower_limit="96.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With 1-year Overall Survival</title>
        <description>The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).</description>
        <time_frame>Time from trial inclusion to death or last day known to be alive, reported between day of first participant included, that is, Jan 2009 until one year after the last participant was included (March 2010)</time_frame>
        <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.</description>
          </group>
          <group group_id="O2">
            <title>Cetuximab 250 mg/m^2 Weekly</title>
            <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 1-year Overall Survival</title>
          <description>The OS time is defined as the time from trial inclusion to death. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is earlier. Percentage of participants who were still alive until one year after the last participant was included (March 2010).</description>
          <population>ITT maintenance analysis set included all participants who were included in ITT (all the participants enrolled in this study) analysis set, judged to be progression-free (based on CT or MRI scan) by the Investigator and randomized to maintenance therapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" lower_limit="54.7" upper_limit="70.0"/>
                    <measurement group_id="O2" value="64.4" lower_limit="56.2" upper_limit="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from Baseline up to 30 days after the last dose of study treatment.</time_frame>
      <desc>One participant who was randomized to ‘Cetuximab 500 mg/m^2 Every 2 Weeks’ arm actually received ‘Cetuximab 250 mg/m^2 Weekly’ treatment and was counted in this group for safety analysis</desc>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy</title>
          <description>Combination Phase: Single first dose of cetuximab 400 milligram per square meter (mg/m^2) infusion administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min weekly (q1w) with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy infusion intravenously as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 mg*hour/milliliter (mg*h/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*h/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Cetuximab 500 mg/m^2 Every 2 Weeks</title>
          <description>Participants who were free of disease progression after combination therapy, they administered with cetuximab 500 mg/m^2 intravenously for 2 weeks, for up to PD, development of unacceptable toxicities, or withdrawal of consent after the end of combination therapy.</description>
        </group>
        <group group_id="E3">
          <title>Cetuximab 250 mg/m^2 Weekly</title>
          <description>Participants who were free of disease progression at the end of combination therapy, entered in the maintenance therapy period. In the maintenance period, participants received cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Febdrile bone marrow aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arrhythmia superaventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Electromechanical dissociation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>C-Reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bronchostenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Femoral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="564" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="136" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="208" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="306" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="583"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Enrollment was stopped prematurely when cetuximab did not gain regulatory approval in this indication.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

